Zealand Pharma slump wipes billions off its value after obesity drug data disappoints | ReutersSkip to main contentExclusive news, data and analytics for financial market professionalsLearn more aboutRefinitivMarch 6 (Reuters) - Shares in Zealand Pharma (ZELA.CO), opens new tab tumbled more than 30% on Friday, putting the Danish biotech firm on track for its worst trading day on record, after mid-stage trial results for obesity drug petrelintide fell short of investor expectations.The drug, which Zealand is ...